Neurogenic bladder (NGB) and neurogenic detrusor overactivity (NDO) manifesting in urinary incontinence (UI) can present substantial treatment challenges to clinicians managing patients with ...

New research by scientists at the University of Nottingham reportedly has shown that overactivity in a specific area of the brain is linked to certain symptoms of schizophrenia, opening up ...

The immune system is crucial to our health. It must sense pathogens and respond to these threats effectively. But the immune system also has to be carefully controlled. If it starts to attack healthy ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said Friday that the U.S. Food and Drug Administration approved Myrbetriq (mirabegron extended-release tablets) for the treatment of NDO in pediatric ...

Injection of botulinum toxin type A into the detrusor smooth muscle is a minimally invasive treatment for incontinence related to neurogenic detrusor overactivity; re-injection is usually necessary ...

The beta-3 adrenergic agonist mirabegron (Myrbetriq) gained an indication for neurogenic detrusor overactivity (NDO), a form of bladder dysfunction, in children 3 and older, the FDA announced Thursday ...

Resistance to standard anticholinergic therapy is a common problem in patients with NEUROGENIC DETRUSOR OVERACTIVITY and incontinence. Intradetrusor injections of botulinum A toxin (BTX-A) are ...

A research team has unveiled the cause and molecular mechanism of chronic brain inflammation that results in repetitive behavioral disorders. The research team demonstrated that an inflammatory ...

(RTTNews) - Allergan, an AbbVie (ABBV) company, announced the FDA has approved BOTOX for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric ...

Experts do not fully understand the exact cause of overactive bladder, but it may involve the involuntary contraction of the detrusor muscle, which controls bladder emptying. Risk factors for ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more. The Food and Drug Administration (FDA) ...